return equiti ttm
reacceler product launch low-risk approv expect
edward releas third-quart result underli revenu million
constant currenc million estim million million
midpoint third-quart guidanc million underli growth within
manag guidanc rang thvt sale came softer expect primarili due
year-over-year market share declin intern tavr market domest growth
line market adjust ep came ahead estim
ahead consensu guidanc driven larg lower tax
rate manag reiter full year guidanc continu expect revenu toward
high end billion rang underli revenu growth exclud
special item foreign exchang guidanc full-year underli tavr
growth expect approxim modestli previou expect
high end driven dynam quarter continu suppli constraint
cardioband mitral system manag reiter bottom-lin guidanc full-year
adjust ep rang
fourth quarter underli revenu adjust ep expect
million billion compar previou estim million consensu
million versu previou estim consensu
achiev target assum continu market dynam
minim impact sapien ultra centera cardioband
catalyst taken longer expect underli market dynam
outlook remain strong new product expect low-risk approv
increas impact throughout year specif expect first self-
expand valv platform centera continu launch europ year next sapien
ultra releas europ year-end ramp two
mitral product cardioband pascal launch broadli european market next
year lastli like approv low-risk patient indic prove
materi catalyst volum remain enthusiast potenti market
edwardss durabl market share posit simpli recent soft preambl
strong trend head share trade time new adjust ep
target view recent sell-off compel buy opportun edward
fundament remain intact rate stock outperform
edward global leader treatment advanc cardiovascular diseas busi divid three
differ segment transcathet heart valv surgic heart valv critic care
conclus stock thought
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
global transcathet heart therapi sale million quarter repres underli sale growth
modestli better last quarter though still midteen market growth estim miss
driven intern price pressur compani seen last sever quarter continu drive
modest year-over-year share loss said manag believ market stabil sequenti basi
even compani maintain price disciplin stabl quarter domest growth
midteen line market growth japan remain fastest-grow region quarter lower base
howev given intern dynam manag tighten expect littl lower expect
full year growth similar saw quarter
despit result remain focus number catalyst tap reacceler growth
intern compani improv expand product offer domest low-risk data
present march approv later year believ opportun could larg impact
compani competit posit long term growth rate next sever year
edward reiter guidanc compani gain regulatori approv next-gener
sapien ultra valv europ year end manag updat investor go-to-
market strategi initi roll-out control compani train clinician devic
expect product ramp throughout domest intern
compani also midst target launch self-expand centera platform intern
similarli benefit result next year edwardss centera compani first self-expand
valv sapien balloon-expand valv wherea competit thvt valv self-expand
edwardss thvt portfolio new design edward appeal physician prefer abil
reposit valv uncomfort rapid pace requir deploy balloon-expand
manag reiter view time impact low-risk patient popul
clinic data expect meet march approv come later year believ
well-conduct clinic trial demonstr tavr compar lower mortal rate
complic profil open chest savr question patient risk profil becom less relev
focu increasingli valv durabl believ even patient age tavr still low
penetr rate address popul suggest opportun even within
remain high greater awar indic expans though dont expect step-wis chang
adopt expect clinic data indic expans increas impact util
throughout beyond
third quarter sale cardioband approxim million came expect
million due on-going manufactur constraint valtech-acquir facil result manag
lower expect cardioband sale fourth quarter approxim million
previou guidanc million full year order ensur volum manag move
product cardioband edward manufactur facil posit step growth long
term push materi impact cardioband accordingli adjust full year
cardioband sale million million million million
respect expect detail cardioband manufactur updat expect system
adopt compani analyst day decemb
look pascal manag highlight earli posit feedback clinician reiter eu
launch sometim edward move forward pivot random control trial
pascal transcathet mitral valv repair system clasp clasp design non-inferior studi
primari endpoint mr grade reduct secondari endpoint advers event studi
expect enrol patient center random pascal mitraclip note manag
decid move forward trial design focus primari mr take advantag work alreadi
done establish clasp trial reiter import secondari mr market well
time launch still determin though edward expect launch europ
look detail compani analyst day decemb
guidanc manag reiter full year revenu guidanc expect sale high end
previous announc billion billion rang manag continu expect thvt sale
high end billion billion shvt sale rang million million critic sale
rang million million on-going cardioband suppli constraint lower expect
full year estim million dollar vs prior guidanc million manag abl
reaffirm total compani sale growth given better-than-expect result critic segment benefit
strong adopt hemospher bottom line manag reiter guidanc adjust earn per
share overal view guidanc achiev expect investor focu
manag outlook compani approach sever meaning catalyst next month
specif look new product cycl sapien ultra centera cardioband well potenti
meaning market expans low-risk tavr data come earli
oper result review edward deliv solid earn per share came midpoint
guided-to rang estim beat primarili driven lower-than-expect tax rate
benefit stock-bas compens account manag suggest still would
beaten estim estim believ compani good firepow continu show
margin expans long term grow ep double-digit rang follow quarter manag reiter
adjust gross margin basi point period last year driven primarili
absenc product expens relat hurrican maria last year manag maintain expect gross
margin sg percentag sale full year expect
adjust tax rate low end previou guided-to rang compani benefit new
account rule relat stock-bas compens
model revenu billion report modestli prior billion
report underli sale basisexclud sale return reserv surgic heart valv
affect full-year report result total millionw estim revenu billion
delta come modestli lower thvt sale estim billion report
underli versu prior estim billion report underli within
manag guidanc rang billion believ estim achiev assum
continu market dynam seen last sever quarter addit conservat tougher comp
fourth quarter
modestli increas adjust ep estim repres growth prior
estim
model revenu billion report underli versu previou estim
billion report underli assum similar growth estim despit
number new product launch like indic expans low-risk popul model
thvt revenu billion report underli manag provid addit
color analyst day decemb though anticip compani expect global market growth
remain midteen rang impli estim assum edward lose modest share new competit
come line conserv estim opinion growth ramp throughout year
model adjust ep year-over-year versu prior estim
delta relat lower tax rate
